The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Kimio Yonesaka, Keita Kudo, Satomi Nishida, Takayuki Takahama, Tsutomu Iwasa, Takeshi Yoshida, Kaoru Tanaka, Masayuki Takeda, Hiroyasu Kaneda, Isamu Okamoto, Kazuto Nishio, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to first generation EGFF-TKIs such as erlotinib. Heregulin activates HER3 in an autocrine fashion and causes erlotinib resistance in NSCLC. Here we examine whether afatinib is effective against heregulinoverexpressing NSCLCs harboring EGFR activating mutations. Afatinib but not erlotinib decreased EGFR mutant NSCLC PC9HRG cell proliferation in vitro and in mouse xenografts. Afatinib inhibited phosphorylation of the cell signaling pathway proteins HER3, EGFR, HER2, and HER4, likely by prevention of trans-phosphorylation as HER3 kinase activity is inadequate for auto-phosphorylation. Afatinib, unlike erlotinib, inhibited AKT activation, resulting in elevated apoptosis in PC9HRG cells. Clinically, a subpopulation of 33 patients with EGFR mutations and NSCLC who had received first generation EGFR-TKIs exhibited elevated plasma heregulin levels compared to healthy volunteers; one of these achieved a response with afatinib therapy despite having previously developed erlotinib resistance. Afatinib can overcome heregulinmediated resistance to erlotinib in EGFR mutant NSCLC. Further studies are necessary to determine whether heregulin can predict afatinib efficacy after development offirst generation EGFR-TKI resistance.

Original languageEnglish
Pages (from-to)33602-33611
Number of pages10
JournalOncotarget
Volume6
Issue number32
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Neuregulin-1
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Ligands
Phosphorylation
Epidermal Growth Factor Receptor
BIBW 2992
Mutation
Heterografts
Erlotinib Hydrochloride
Healthy Volunteers
Phosphotransferases
Cell Proliferation
Apoptosis

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. / Yonesaka, Kimio; Kudo, Keita; Nishida, Satomi; Takahama, Takayuki; Iwasa, Tsutomu; Yoshida, Takeshi; Tanaka, Kaoru; Takeda, Masayuki; Kaneda, Hiroyasu; Okamoto, Isamu; Nishio, Kazuto; Nakagawa, Kazuhiko.

In: Oncotarget, Vol. 6, No. 32, 01.01.2015, p. 33602-33611.

Research output: Contribution to journalArticle

Yonesaka, K, Kudo, K, Nishida, S, Takahama, T, Iwasa, T, Yoshida, T, Tanaka, K, Takeda, M, Kaneda, H, Okamoto, I, Nishio, K & Nakagawa, K 2015, 'The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer', Oncotarget, vol. 6, no. 32, pp. 33602-33611. https://doi.org/10.18632/oncotarget.5286
Yonesaka, Kimio ; Kudo, Keita ; Nishida, Satomi ; Takahama, Takayuki ; Iwasa, Tsutomu ; Yoshida, Takeshi ; Tanaka, Kaoru ; Takeda, Masayuki ; Kaneda, Hiroyasu ; Okamoto, Isamu ; Nishio, Kazuto ; Nakagawa, Kazuhiko. / The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. In: Oncotarget. 2015 ; Vol. 6, No. 32. pp. 33602-33611.
@article{c6028da981c34f8ebd01d3dd0b20ad15,
title = "The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer",
abstract = "Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to first generation EGFF-TKIs such as erlotinib. Heregulin activates HER3 in an autocrine fashion and causes erlotinib resistance in NSCLC. Here we examine whether afatinib is effective against heregulinoverexpressing NSCLCs harboring EGFR activating mutations. Afatinib but not erlotinib decreased EGFR mutant NSCLC PC9HRG cell proliferation in vitro and in mouse xenografts. Afatinib inhibited phosphorylation of the cell signaling pathway proteins HER3, EGFR, HER2, and HER4, likely by prevention of trans-phosphorylation as HER3 kinase activity is inadequate for auto-phosphorylation. Afatinib, unlike erlotinib, inhibited AKT activation, resulting in elevated apoptosis in PC9HRG cells. Clinically, a subpopulation of 33 patients with EGFR mutations and NSCLC who had received first generation EGFR-TKIs exhibited elevated plasma heregulin levels compared to healthy volunteers; one of these achieved a response with afatinib therapy despite having previously developed erlotinib resistance. Afatinib can overcome heregulinmediated resistance to erlotinib in EGFR mutant NSCLC. Further studies are necessary to determine whether heregulin can predict afatinib efficacy after development offirst generation EGFR-TKI resistance.",
author = "Kimio Yonesaka and Keita Kudo and Satomi Nishida and Takayuki Takahama and Tsutomu Iwasa and Takeshi Yoshida and Kaoru Tanaka and Masayuki Takeda and Hiroyasu Kaneda and Isamu Okamoto and Kazuto Nishio and Kazuhiko Nakagawa",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5286",
language = "English",
volume = "6",
pages = "33602--33611",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

TY - JOUR

T1 - The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

AU - Yonesaka, Kimio

AU - Kudo, Keita

AU - Nishida, Satomi

AU - Takahama, Takayuki

AU - Iwasa, Tsutomu

AU - Yoshida, Takeshi

AU - Tanaka, Kaoru

AU - Takeda, Masayuki

AU - Kaneda, Hiroyasu

AU - Okamoto, Isamu

AU - Nishio, Kazuto

AU - Nakagawa, Kazuhiko

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to first generation EGFF-TKIs such as erlotinib. Heregulin activates HER3 in an autocrine fashion and causes erlotinib resistance in NSCLC. Here we examine whether afatinib is effective against heregulinoverexpressing NSCLCs harboring EGFR activating mutations. Afatinib but not erlotinib decreased EGFR mutant NSCLC PC9HRG cell proliferation in vitro and in mouse xenografts. Afatinib inhibited phosphorylation of the cell signaling pathway proteins HER3, EGFR, HER2, and HER4, likely by prevention of trans-phosphorylation as HER3 kinase activity is inadequate for auto-phosphorylation. Afatinib, unlike erlotinib, inhibited AKT activation, resulting in elevated apoptosis in PC9HRG cells. Clinically, a subpopulation of 33 patients with EGFR mutations and NSCLC who had received first generation EGFR-TKIs exhibited elevated plasma heregulin levels compared to healthy volunteers; one of these achieved a response with afatinib therapy despite having previously developed erlotinib resistance. Afatinib can overcome heregulinmediated resistance to erlotinib in EGFR mutant NSCLC. Further studies are necessary to determine whether heregulin can predict afatinib efficacy after development offirst generation EGFR-TKI resistance.

AB - Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to first generation EGFF-TKIs such as erlotinib. Heregulin activates HER3 in an autocrine fashion and causes erlotinib resistance in NSCLC. Here we examine whether afatinib is effective against heregulinoverexpressing NSCLCs harboring EGFR activating mutations. Afatinib but not erlotinib decreased EGFR mutant NSCLC PC9HRG cell proliferation in vitro and in mouse xenografts. Afatinib inhibited phosphorylation of the cell signaling pathway proteins HER3, EGFR, HER2, and HER4, likely by prevention of trans-phosphorylation as HER3 kinase activity is inadequate for auto-phosphorylation. Afatinib, unlike erlotinib, inhibited AKT activation, resulting in elevated apoptosis in PC9HRG cells. Clinically, a subpopulation of 33 patients with EGFR mutations and NSCLC who had received first generation EGFR-TKIs exhibited elevated plasma heregulin levels compared to healthy volunteers; one of these achieved a response with afatinib therapy despite having previously developed erlotinib resistance. Afatinib can overcome heregulinmediated resistance to erlotinib in EGFR mutant NSCLC. Further studies are necessary to determine whether heregulin can predict afatinib efficacy after development offirst generation EGFR-TKI resistance.

UR - http://www.scopus.com/inward/record.url?scp=84946023279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946023279&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5286

DO - 10.18632/oncotarget.5286

M3 - Article

VL - 6

SP - 33602

EP - 33611

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -